Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial
Intend to provide an update on expanded development of zotatifin
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial
Intend to provide an update on expanded development of zotatifin
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| EFTR | 0.0002 | unch | unch |
| Effector Therapeutics Inc | |||